Related Experiment Video

Updated: Aug 15, 2026

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease

J C H van Oostrom1, R P Maguire, C C Verschuuren-Bemelmans

  • 1Department of Neurology, Groningen University Medical Center, Groningen, The Netherlands.

Neurology
|September 28, 2005
PubMed

Insights

Huntington disease mutation carriers show early dopamine D2 receptor changes. Raclopride PET binding potential (RAC-BP) decreased in 50%, indicating potential neuronal impairment before other markers.

Area of Science:

  • Neuroscience
  • Genetics
  • Radiology

Background:

  • Huntington disease (HD) is an inherited neurodegenerative disorder.
  • Preclinical carriers of the HD mutation (PMC) may exhibit subtle, early changes.
  • Identifying sensitive biomarkers for early neuronal impairment is crucial.

Purpose of the Study:

  • To investigate early neuronal changes in preclinical carriers of the Huntington disease mutation (PMC).
  • To assess the sensitivity of dopamine D2 receptor availability as an early indicator of HD-related neuronal impairment.

Main Methods:

  • Utilized MRI volumetry to assess striatal volumes in 27 PMCs.
  • Employed fluorodesoxyglucose (FDG) PET to measure metabolic index.
  • Measured raclopride PET binding potential (RAC-BP) to quantify dopamine D2 receptor availability.

Main Results:

  • 88% of PMCs had normal striatal volumes on MRI.
  • 67% of PMCs showed a normal metabolic index on FDG PET.
  • 50% of PMCs exhibited decreased RAC-BP, correlating with age and CAG repeat length (p < 0.0005).

Conclusions:

  • Dopamine D2 receptor availability, measured by RAC-BP, is a sensitive indicator of early neuronal impairment in PMCs.
  • RAC-BP may detect changes before structural or metabolic alterations become apparent.
  • This finding highlights the potential of dopaminergic imaging in preclinical HD detection.

More Related Videos

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.